Session IV: Gastrointestinal Stromal Tumors (GIST); Neuroendocrine Tumors (NET)
FULL ABSTRACTS AVAILABLE SATURDAY JULY 4
The authors conclude that in phase 3 randomized INVICTUS trial, pts with 4th-line GIST exhibited a clinically meaningful benefit from ripretinib after crossover from placebo and had a well-tolerated safety profile that was generally consistent with previously reported data from the double-blind period. The median PFS2 (from initiation of ripretinib treatment to progression) for pts that crossed over to ripretinib was 4.6 months. The median OS for pts that crossed over to ripretinib was 11.6 months.
The data suggest that for pts who were able to cross over, ripretinib established disease control despite delayed initiation of treatment; however, maximum benefit is achieved when ripretinib is used immediately after failure of prior therapy in pts with ≥4th-line advanced GIST. Enrolment is ongoing in INTRIGUE (NCT03673501)
The authors conclude that most young adults with NETs have a family history of cancer (nearly 70%) Nearly 175th present a pathogenic or probably pathogenic germline variant in cancer-predisposing genes, with most affected genes being involved in DNA repair mechanisms. Midgut and pancreas were the most common tumor sites and except for one case, all were G1/G2 NET. Compared to sporadic cases, those w germline mutations were similar in terms of sex and age of onset.